Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glaxo And Novartis Scratch Each Other’s Back With Consumer Product JV

This article was originally published in The Tan Sheet

Executive Summary

The combination of the firm’s consumer portfolios will create the No. 1 global OTC business, Duetsche Bank analysts say. GSK estimates OTC sales from JV will reach $5.72 billion, representing more than half of the $10 billion in overall annual sales anticipated for the consumer health product JV.

You may also be interested in...



‘Increasingly Challenging’ Environment Shifted J&J's Plans Toward Consumer Business Separation

Pharma R&D VP Mathai Mammen acknowledges “pros and cons to remaining” as one company but dismissed “any meaningful downside” for the pharma business, which along with the device business will continue operating as J&J.

J&J Rides Standalone Consumer Health Track

J&J takes same approach GSK, Pfizer, Merck & Co, Merck and Novartis have with their consumer health businesses, Bausch Health is starting and Sanofi says it will.

Glaxo Opts For Solo Navigation To Boost Control In Consumer Health Market

After announcing the $13bn acquisition of Novartis' 36.5% share of their JV, GSK said its Horlicks nutritional beverage line and its consumer health subsidiary in India, the source of most Horlicks sales, are potential divestments. The firm also will consider selling other consumer health nutrition products.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS106863

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel